Related Experiment Videos
Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets
M Petrikova1, V Jancinova, R Nosal
1Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava, Slovakia. exfapegi@savba.sk
Bratislavske Lekarske Listy
|May 5, 2005
Summary
Carvedilol and propranolol inhibit platelet aggregation and thromboxane B2 formation. Carvedilol is more potent than propranolol and atenolol, suggesting its unique molecular structure enhances antiplatelet activity.
Area of Science:
- Cardiovascular Pharmacology
- Hematology
- Medicinal Chemistry
Background:
- Platelets are crucial in pathological conditions.
- Beta-blockers influence platelet aggregation.
- Carvedilol's antiplatelet effects are not well-documented.
Purpose of the Study:
- Evaluate carvedilol's in vitro antiplatelet activity.
- Compare carvedilol with propranolol and atenolol.
- Assess thromboxane B2 formation and physico-chemical properties.
Main Methods:
- Isolated human platelets via differential centrifugation.
- Measured platelet aggregation using turbidimetric method.
- Quantified thromboxane B2 via radioimmunoassay; calculated drug physico-chemical parameters.
Main Results:
- Carvedilol and propranolol inhibited platelet aggregation (PMA > thrombin > A23187 > epinephrine), reducing thromboxane B2.
- Carvedilol showed greater efficacy than propranolol, except for ADP-stimulated aggregation.
- Atenolol had no effect; carvedilol exhibited superior partition coefficient, molar refractivity, and lower dipole moment.
Conclusions:
- Carvedilol is more potent than propranolol and atenolol in inhibiting platelet aggregation and thromboxane B2 production.
- Carvedilol's enhanced antiplatelet activity may stem from its molecular structure and physico-chemical properties.